Audentes Becomes Astellas Gene Therapies, Will Advance MD Treatments

Audentes Becomes Astellas Gene Therapies, Will Advance MD Treatments

291171

Audentes Becomes Astellas Gene Therapies, Will Advance MD Treatments

Following its acquisition last year by Astellas Pharma, Audentes Therapeutics now has become Astellas Gene Therapies. Named a Gene Therapy Center of Excellence, it will work to advance the development of potentially life-changing gene therapies for several conditions, including muscular dystrophy (MD). “The field of gene therapy has made significant strides to date, and we believe the future holds even greater opportunity to bring new treatments to a wide range of diseases for patients in need,”…

You must be logged in to read/download the full post.